Methods of reducing inflammation and mucus hypersecretion
Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.
1. A method of decreasing MARCKS-related mucus secretion and MARCKS-related release of mediators of inflammation from infiltrating inflammatory cells in tissues of a subject in need thereof comprising: administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with an N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein, in a dual function therapeutically effective amount to reduce MARCKS-related secretion of at least one inflammatory mediator from at least one inflammatory cell in said subject and to reduce MARCKS-related mucus hypersecretion from at least one mucus secreting cell or tissue in said subject, whereby inflammation and mucus hypersecretion in said subject are reduced compared to that which would occur in the absence of said administration of said pharmaceutical composition, wherein said inflammatory mediator is secreted from an infiltrating inflammatory cell at a site of inflammation in the subject, and wherein said inflammation and mucus hypersecretion are caused by or are the clinical symptoms of a respiratory disease.
2. The method according to claim 1 , wherein said N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein consists of the myristoylated N- terminal peptide (SEQ ID NO:1) or a N-terminal myristoylated peptide fragment thereof consisting of at least five contiguous amino acids of SEQ ID NO:1.
3. The method according to claim 2 , wherein said N-terminal myristoylated peptide fragment consists of at least 10 amino acids of SEQ ID NO: 1.
4. The method according to claim 2 , wherein said N-terminal myristoylated peptide fragment consists of at least 15 amino acids of SEQ ID NO: 1.
5. The method according to claim 2 , wherein said N-terminal myristoylated peptide fragment consists of at least 20 amino acids of SEQ ID NO: 1.
6. The method according to claim 2 , wherein said N-terminal myristoylated peptide fragment is selected from the group consisting of N-myristoyl-GAQFSKTAAKGEAAAERPGEAAV (SEQ ID NO: 2); N-myristoyl-GAQFSKTAAKGEAAAERPGEAA (SEQ ID NO: 3); N-myristoyl-GAQFSKTAAKGEAAAERPGEA (SEQ ID NO: 4); N-myristoyl-GAQFSKTAAKGEAAAERPGE (SEQ ID NO: 5); N-myristoyl-GAQFSKTAAKGEAAAERPG (SEQ ID NO: 6); N-myristoyl-GAQFSKTAAKGEAAAERP (SEQ ID NO: 7); N-myristoyl-GAQFSKTAAKGEAAAER (SEQ ID NO: 8); N-myristoyl-GAQFSKTAAKGEAAAE (SEQ ID NO: 9); N-myristoyl-GAQFSKTAAKGEAAA (SEQ ID NO: 10); N-myristoyl-GAQFSKTAAKGEAA (SEQ ID NO: 11); N-myristoyl-GAQFSKTAAKGEA (SEQ ID NO: 12); N-myristoyl-GAQFSKTAAKGE (SEQ ID NO: 13); N-myristoyl-GAQFSKTAAKG (SEQ ID NO: 14); N-myristoyl-GAQFSKTAAK (SEQ ID NO: 15); N-myristoyl-GAQFSKTAA (SEQ ID NO: 16); N-myristoyl-GAQFSKTA (SEQ ID NO: 17); N-myristoyl-GAQFSKT (SEQ ID NO: 18); N-myristoyl-GAQFSK (SEQ ID NO: 19); and N-myristoyl-GAQFS (SEQ ID NO: 20).
7. A method of decreasing MARCKS-related mucus secretion and MARCKS-related release of mediators of inflammation from infiltrating inflammatory cells in tissues of a subject in need thereof comprising:
administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of N-terminal myristoylated protein fragments of the N- terminal region of MARCKS protein, which fragments are selected from the group consisting of N-myristoyl-GAQFSKTAAKGEAAAERPGEAAVA (SEQ ID NO: 1); N-myristoyl-GAQFSKTAAKGEAAAERPGEAAV (SEQ ID NO: 2); N-myristoyl-GAQFSKTAAKGEAAAERPGEAA (SEQ ID NO: 3); N-myristoyl-GAQFSKTAAKGEAAAERPGEA (SEQ ID NO: 4); N-myristoyl-GAQFSKTAAKGEAAAERPGE (SEQ ID NO: 5); N-myristoyl-GAQFSKTAAKGEAAAERPG (SEQ ID NO: 6); N-myristoyl-GAQFSKTAAKGEAAAERP (SEQ ID NO: 7); N-myristoyl-GAQFSKTAAKGEAAAER (SEQ ID NO: 8); N-myristoyl-GAQFSKTAAKGEAAAE (SEQ ID NO: 9); N-myristoyl-GAQFSKTAAKGEAAA (SEQ ID NO: 10); N-myristoyl-GAQFSKTAAKGEAA (SEQ ID NO: 11); N-myristoyl-GAQFSKTAAKGEA (SEQ ID NO: 12); N-myristoyl-GAQFSKTAAKGE (SEQ ID NO: 13); N-myristoyl-GAQFSKTAAKG (SEQ ID NO: 14); N-myristoyl-GAQFSKTAAK (SEQ ID NO: 15); N-myristoyl-GAQFSKTAA (SEQ ID NO: 16); N-myristoyl-GAQFSKTA (SEQ ID NO: 17); N-myristoyl-GAQFSKT (SEQ ID NO: 18); N-myristoyl-GAQFSK (SEQ ID NO: 19); and N-myristoyl-GAQFS (SEQ ID NO: 20).
8. The method according to claim 7 , wherein said pharmaceutical composition comprises a combination selected from two of said N-terminal myristoylated protein fragments.
9. The method according to claim 1 , wherein said respiratory disease is selected from the group consisting of asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, pneumonia, influenza, rhinitis, and the common cold.
10. The method according to claim 1 , wherein said respiratory disease is selected from the group consisting of asthma, chronic bronchitis, and COPD.
11. The method according to claim 1 , wherein said subject is a mammal.
12. The method according to claim 1 , wherein said administering is selected from the group consisting of topical administration, parenteral administration, rectal administration, pulmonary administration, inhalation administration, nasal administration, and oral administration.
13. The method according to claim 12 , wherein said pulmonary administration comprises use of an aerosol from a dry powder inhaler, from a metered dose inhaler, or from a nebulizer.
14. The method according to claim 1 , wherein said inflammatory cell is a leukocyte.
15. The method according to claim 1 , wherein said inflammatory cell is a granulocyte.
16. The method according to claim 1 , wherein said inflammatory cell is selected from the group consisting of a neutrophil, a basophil, an eosinophil, a monocyte, a macrophage, and a mast cell.
17. The method according to claim 1 , wherein the therapeutically effective amount of the pharmaceutical composition is administered orally, parenterally, rectally, or through an air passage.
18. The method according to claim 1 , further comprising administering to said subject an additional agent selected from the group consisting of an antibiotic, an antiviral compound, an antiparasitic compound, an anti-inflammatory compound, and an immunosuppressant.
19. The method according to claim 1 , wherein said mucus secreting cell is an epithelial cell in the airways of said subject.
20. A method of decreasing the MARCKS-related release of mediators of inflammation from infiltrating inflammatory cells of a subject in need thereof comprising: administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with an N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein, in a therapeutically effective amount to reduce MARCKS-related release of at least one inflammatory mediator from at least one inflammatory cell in said subject, whereby inflammation in said subject is reduced compared to that which would occur in the absence of said administration of said pharmaceutical composition, wherein said inflammatory mediator is secreted from an infiltrating inflammatory cell at a site of inflammation in the subject, and wherein said inflammation is caused by or is a major clinical symptom of a bowel disease, a skin disease, an autoimmune disease or a pain syndrome.
21. The method according to claim 20 , wherein said N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein consists of the N-terminal myristoylated peptide (SEQ ID NO:1) or a N-terminal myristoylated peptide fragment thereof consisting of at least five contiguous amino acids of SEQ ID NO:1.
22. The method according to claim 21 , wherein said N-terminal myristoylated peptide fragment consists of at least 10 amino acids of SEQ ID NO: 1.
23. The method according to claim 21 , wherein said N-terminal myristoylated peptide fragment consists of at least 15 amino acids of SEQ ID NO: 1.
24. The method according to claim 21 , wherein said N-terminal myristoylated peptide fragment consists of at least 20 amino acids of SEQ ID NO: 1.
25. The method according to claim 21 , wherein said N-terminal myristoylated peptide fragment is selected from the group consisting of N-myristoyl-GAQFSKTAAKGEAAAERPGEAAV (SEQ ID NO: 2); N-myristoyl-GAQFSKTAAKGEAAAERPGEAA (SEQ ID NO: 3); N-myristoyl-GAQFSKTAAKGEAAAERPGEA (SEQ ID NO: 4); N-myristoyl-GAQFSKTAAKGEAAAERPGE (SEQ ID NO: 5); N-myristoyl-GAQFSKTAAKGEAAAERPG (SEQ ID NO: 6); N-myristoyl-GAQFSKTAAKGEAAAERP (SEQ ID NO: 7); N-myristoyl-GAQFSKTAAKGEAAAER (SEQ ID NO: 8); N-myristoyl-GAQFSKTAAKGEAAAE (SEQ ID NO: 9); N-myristoyl-GAQFSKTAAKGEAAA (SEQ ID NO: 10); N-myristoyl-GAQFSKTAAKGEAA (SEQ ID NO: 11); N-myristoyl-GAQFSKTAAKGEA (SEQ ID NO: 12); N-myristoyl-GAQFSKTAAKGE (SEQ ID NO: 13); N-myristoyl-GAQFSKTAAKG (SEQ ID NO: 14); N-myristoyl-GAQFSKTAAK (SEQ ID NO: 15); N-myristoyl-GAQFSKTAA (SEQ ID NO: 16); N-myristoyl-GAQFSKTA (SEQ ID NO: 17); N-myristoyl-GAQFSKT (SEQ ID NO: 18); N-myristoyl-GAQFSK (SEQ ID NO: 19); and N-myristoyl-GAQFS (SEQ ID NO: 20).
26. The method according to claim 20 , wherein said inflammatory cell is a leukocyte.
27. The method according to claim 20 , wherein said inflammatory cell is a granulocyte.
28. The method according to claim 20 , wherein said inflammatory cell is selected from the group consisting of a neutrophil, a basophil, an eosinophil, a monocyte, a macrophage, and a mast cell.
29. The method according to claim 20 , further comprising administering to said subject an additional agent selected from the group consisting of an antibiotic, an antiviral compound, an antiparasitic compound, an anti-inflammatory compound, and an immunosuppressant.
30. The method according to claim 20 , wherein said inflammation is caused by or is a clinical symptom of arthritis, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, irritable bowel syndrome, psoriasis, rosacea, eczema, psoriasis, severe acne, systemic lupus erythematosus, or insulin-dependent diabetes mellitus.
31. The method according to claim 20 , wherein said administering is selected from the group consisting of topical administration, parenteral administration, rectal administration, pulmonary administration, inhalation administration, nasal administration, and oral administration.